|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/5/2012 7:16:02 AM
The bleeding continues. AstraZeneca is eliminating up to 625 jobs from its operations in Germany in response to difficulties replenishing its product pipeline and pricing cuts imposed by the government, according to a statement on its web site. The cuts are being made due to “delays in the research and development of new drugs as well as to massive state intervention in the pricing of innovative medicines,” the drug maker says. In the scheme of things, 625 positions is not a huge number of job cuts, given the thousands that have been shed by the pharmaceutical industry, including AstraZeneca. Earlier this year, for instance, the drugmaker announced plans to slash 7,300 jobs. It is not clear if the job cuts in Germany are part of this previously announced plan. We asked a spokeperson for comment and will update you accordingly. As we wrote previously, those cuts are designed to save $1.6 billion annually by the end of 2014 and underscore the fallout expected from patent expirations on some of its biggest sellers, notably the Crestor cholesterol pill, the Nexium acid reflux med and the Seroquel antipsychotic.
|
|
|
|
|
|
|
|
|
|
|